Arca
Skip to content

Warning Letter to Goran Pharma Pvt Ltd

Unspecified. See Goran Pharma's company page or this site's inspections.

On Apr 24, 2018, FDA's CDER sent Goran Pharma Pvt Ltd a warning letter citing sterility assurance, supplier controls, quality unit.

  • Letter date: Apr 24, 2018
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

• a detailed description of how you will ensure that components (e.g., ingredients) used in the manufacture of your drug products will be withheld from use until the lot has been tested in accordance with the current United States Pharmacopoeia (USP) and released for use by the quality unit;

• an improved procedure that describes how you qualify your suppliers’ COA both initially and on an ongoing basis. Explain whether you intend to test each lot of incoming components for all attributes instead of relying on the suppliers’ COA. Alternatively, if you intend to rely on the supplier’s COA, provide specifics on how you will verify each supplier’s test results at regular intervals and include a commitment to test at minimum every incoming component lot for USP identity requirements.

• a detailed risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. As part of your risk assessment, immediately test retained samples of all lots for DEG and EG, and take appropriate market action if the testing yields any aberrant results.

• a comprehensive, independent review of your laboratory practices, methods, equipment, and analyst competencies. Based on this review, provide a detailed corrective action and preventive action (CAPA) plan to remediate your laboratory systems.

• a detailed plan for validation of the new (b)(4) system

• procedures for routine monitoring of the (b)(4) system as well as system control and maintenance

• scientific justification for the frequency, (b)(4), and duration that you will use to sanitize the (b)(4) system

• a risk assessment for products manufactured prior to installation and validation of the new (b)(4) system

• your rationale for relying on past data to characterize the (b)(4) system’s state of control, given the microbiology laboratory deficiencies noted during the inspection.

• a detailed action plan for ensuring adequate control and monitoring of temperature, humidity, and air cleanliness in your facility

• a comprehensive, independent assessment of your facilities and equipment. This assessment should include a full evaluation of the suitability of the design, control, and maintenance of your equipment and facilities. Based on this review, provide a detailed CAPA plan.

Recent Letters Citing Sterility assurance

See them all

Record

Recipient
—
FDA site ID (FEI)
3009336980

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.